Karmanos Cancer Hospital
- Type
- Teaching hospital
- Where
- Detroit, MI
- Medicare CCN
- 230297
- Received
- $10,706,325 in 1,836 records, 2021 ($32,500 general, $10,673,825 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 5 | $32,500 |
| 2021 | Research payment | 1,831 | $10,673,825 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,831 | $10,673,825 |
| Space rental or facility fees (teaching hospital only) | 2 | $12,500 |
| Charitable Contribution | 1 | $10,000 |
| Grant | 2 | $10,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $552,500 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label Phase 1b,2a Study of NT-I7 Hyleukin-7 in Combination with Pembrolizumab in Subjects with Relapsed,Refracto | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $138,749 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $130,964 | Research payment | In-kind items and services | Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $130,299 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $86,306 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $52,313 | Research payment | In-kind items and services | Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $44,335 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $43,568 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatin | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $39,090 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $38,773 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab MK-7684 with Pembrolizumab M | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $32,569 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $29,129 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $27,000 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatin | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $26,546 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $22,728 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $20,305 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $17,351 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $15,696 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $15,680 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $15,176 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $13,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $12,755 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,801 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $6,742 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously S | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $6,599 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $5,229 | Research payment | In-kind items and services | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) i | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $5,154 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,813 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,359 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,982 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,066 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,785 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refracto | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,779 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,087 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-1 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,962 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $1,550 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,355 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,183 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $628 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1,2a Study of Double-Immune Suppression Blockade by Combining a CSF1R Inhibitor PLX3397 with an Anti-PD-1 Antibody | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $608 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase Ib Trial of Pembrolizumab MK-3475 in Combination with Dinaciclib MK-7965 in Subjects with Hematologic Malignancies | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $158 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $96 | Research payment | In-kind items and services | Study of MEDI4736 Durvalumab With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $75 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Met | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Recurrent Ovari | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with | 2021 |
| 2021-12-30 | Pharmacyclics LLC, an AbbVie Company | $46,127 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | A phase II multicenter single arm study to evaluate the efficacy and safety of single agent Brutons tyrosine kinase inhi | 2021 |
| 2021-12-30 | Novocure Inc. | $1,000 | Research payment | Cash or cash equivalent | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2021 | |
| 2021-12-30 | Novocure Inc. | $1,000 | Research payment | Cash or cash equivalent | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2021 | |
| 2021-12-29 | Merck Sharp & Dohme LLC | $89,409 | Research payment | Cash or cash equivalent | Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2021 |
| 2021-12-29 | Gilead Sciences, Inc. | $20,800 | Research payment | Cash or cash equivalent | A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma | 2021 | |
| 2021-12-29 | Merck Sharp & Dohme LLC | $5,740 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously S | 2021 |
| 2021-12-29 | Boehringer Ingelheim International GmbH | $4,880 | Research payment | Cash or cash equivalent | BI 754091 first-in-man dose escalation | 2021 | |
| 2021-12-28 | TRILLIUM THERAPEUTICS USA, LLC | $2,310 | Research payment | Cash or cash equivalent | A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L | 2021 | |
| 2021-12-28 | TRILLIUM THERAPEUTICS USA, LLC | $1,500 | Research payment | Cash or cash equivalent | A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L | 2021 | |
| 2021-12-28 | Daiichi Sankyo Inc. | $1,500 | Research payment | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | DS-8201-A-U204 | 2021 |
| 2021-12-28 | TRILLIUM THERAPEUTICS USA, LLC | $1,422 | Research payment | Cash or cash equivalent | A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L | 2021 | |
| 2021-12-28 | TRILLIUM THERAPEUTICS USA, LLC | $1,422 | Research payment | Cash or cash equivalent | A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L | 2021 | |
| 2021-12-28 | TRILLIUM THERAPEUTICS USA, LLC | $1,422 | Research payment | Cash or cash equivalent | A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L | 2021 | |
| 2021-12-28 | Daiichi Sankyo Inc. | $1,357 | Research payment | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | DS-8201-A-U204 | 2021 |
| 2021-12-28 | TRILLIUM THERAPEUTICS USA, LLC | $1,000 | Research payment | Cash or cash equivalent | A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L | 2021 | |
| 2021-12-28 | TRILLIUM THERAPEUTICS USA, LLC | $990 | Research payment | Cash or cash equivalent | A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L | 2021 | |
| 2021-12-27 | Janssen Research & Development, LLC | $1,108 | Research payment | Cash or cash equivalent | A Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub | 2021 | |
| 2021-12-27 | Takeda Pharmaceuticals U.S.A., Inc. | $1,016 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2021 | |
| 2021-12-27 | Janssen Research & Development, LLC | $838 | Research payment | Cash or cash equivalent | A Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub | 2021 | |
| 2021-12-24 | Ipsen Bioscience Inc. | $2,750 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-24 | Janssen Research & Development, LLC | $2,000 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2021 | |
| 2021-12-23 | Janssen Research & Development, LLC | $488 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2021 | |
| 2021-12-22 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-22 | Takeda Pharmaceuticals U.S.A., Inc. | $5,331 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2021 | |
| 2021-12-22 | Regeneron Pharmaceuticals, Inc. | $3,987 | Research payment | Cash or cash equivalent | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN | 2021 | |
| 2021-12-22 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-22 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-22 | Alkermes, Inc. | $2,400 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-22 | Theratechnologies Inc. | $2,200 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients With Advanced Solid Tumors and Expansion in Patients | 2021 | |
| 2021-12-22 | Alkermes, Inc. | $1,676 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-22 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | ALUNBRIG Drug, ONCOLOGY | BRIGATINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+), ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PROG | 2021 |
| 2021-12-22 | Regeneron Pharmaceuticals, Inc. | $1,376 | Research payment | Cash or cash equivalent | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN | 2021 | |
| 2021-12-22 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HA | 2021 |
| 2021-12-22 | PFIZER INC. | $990 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HA | 2021 |
| 2021-12-22 | PFIZER INC. | $528 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HA | 2021 |
| 2021-12-22 | Incyte Corporation | $200 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due t | 2021 | |
| 2021-12-22 | Alkermes, Inc. | $79 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-21 | Pharmacyclics LLC, an AbbVie Company | $59,680 | Research payment | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | A phase II multicenter single arm study to evaluate the efficacy and safety of single agent Brutons tyrosine kinase inhi | 2021 |
| 2021-12-21 | Daiichi Sankyo Inc. | $3,068 | Research payment | Cash or cash equivalent | Turalio Drug, ONCOLOGY | PL3397-A-U126 | 2021 |
| 2021-12-21 | Daiichi Sankyo Inc. | $2,666 | Research payment | Cash or cash equivalent | Turalio Drug, ONCOLOGY | PL3397-A-U126 | 2021 |
| 2021-12-21 | Daiichi Sankyo Inc. | $696 | Research payment | Cash or cash equivalent | Turalio Drug, ONCOLOGY | PL3397-A-U126 | 2021 |
| 2021-12-21 | Daiichi Sankyo Inc. | $696 | Research payment | Cash or cash equivalent | Turalio Drug, ONCOLOGY | PL3397-A-U126 | 2021 |
| 2021-12-21 | Daiichi Sankyo Inc. | $696 | Research payment | Cash or cash equivalent | Turalio Drug, ONCOLOGY | PL3397-A-U126 | 2021 |
| 2021-12-21 | Daiichi Sankyo Inc. | $696 | Research payment | Cash or cash equivalent | Turalio Drug, ONCOLOGY | PL3397-A-U126 | 2021 |
| 2021-12-21 | Daiichi Sankyo Inc. | $696 | Research payment | Cash or cash equivalent | Turalio Drug, ONCOLOGY | PL3397-A-U126 | 2021 |
| 2021-12-21 | Daiichi Sankyo Inc. | $696 | Research payment | Cash or cash equivalent | Turalio Drug, ONCOLOGY | PL3397-A-U126 | 2021 |
| 2021-12-20 | Genentech, Inc. | $11,178 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2021 |
| 2021-12-20 | Genentech, Inc. | $8,539 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2021 |
| 2021-12-20 | Genentech, Inc. | $5,060 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2021 |
| 2021-12-20 | Genentech, Inc. | $5,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2021 |
| 2021-12-20 | Janssen Research & Development, LLC | $4,100 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2021 | |
| 2021-12-20 | Janssen Research & Development, LLC | $1,746 | Research payment | Cash or cash equivalent | A Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub | 2021 | |
| 2021-12-20 | Exelixis Inc. | $1,019 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2021 |
| 2021-12-20 | Janssen Research & Development, LLC | $398 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2021 | |
| 2021-12-17 | Theratechnologies Inc. | $5,278 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients With Advanced Solid Tumors and Expansion in Patients | 2021 | |
| 2021-12-17 | Regeneron Pharmaceuticals, Inc. | $3,500 | Research payment | Cash or cash equivalent | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN | 2021 | |
| 2021-12-17 | Janssen Research & Development, LLC | $2,204 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit | 2021 | |
| 2021-12-17 | Regeneron Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN | 2021 | |
| 2021-12-17 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit | 2021 | |
| 2021-12-17 | Janssen Research & Development, LLC | $1,320 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit | 2021 | |
| 2021-12-17 | Regeneron Pharmaceuticals, Inc. | $816 | Research payment | Cash or cash equivalent | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN | 2021 | |
| 2021-12-17 | Janssen Research & Development, LLC | $200 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2021 | |
| 2021-12-17 | Corcept Therapeutics | $200 | Research payment | Cash or cash equivalent | CORT125134-553 | 2021 | |
| 2021-12-17 | Janssen Research & Development, LLC | $70 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $16,310 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $15,787 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-16 | Janssen Research & Development, LLC | $8,363 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit | 2021 | |
| 2021-12-16 | Daiichi Sankyo Inc. | $6,247 | Research payment | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | DS-8201-A-U204 | 2021 |
| 2021-12-16 | Janssen Research & Development, LLC | $2,271 | Research payment | Cash or cash equivalent | An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with B | 2021 | |
| 2021-12-16 | Karyopharm Therapeutics Inc. | $2,000 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Multicenter, Phase 1/2 Study of Selinexor in Combination with Backbone Treatments or Novel Therapies in Patients with | 2021 |
| 2021-12-16 | Janssen Research & Development, LLC | $2,000 | Research payment | Cash or cash equivalent | An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with B | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $1,500 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2021 | |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2021 | |
| 2021-12-16 | Janssen Research & Development, LLC | $1,360 | Research payment | Cash or cash equivalent | An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with B | 2021 | |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $1,320 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $1,320 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2021 | |
| 2021-12-16 | Novocure Inc. | $1,075 | Research payment | Cash or cash equivalent | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $1,000 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2021 | |
| 2021-12-16 | Novocure Inc. | $1,000 | Research payment | Cash or cash equivalent | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2021 | |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2021 | |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $792 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2021 | |
| 2021-12-16 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $385 | Research payment | In-kind items and services | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $123 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-16 | Alkermes, Inc. | $68 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-15 | Merck Sharp & Dohme LLC | $53,281 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2021 |
| 2021-12-15 | Merck Sharp & Dohme LLC | $23,566 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A | 2021 |
| 2021-12-15 | BeiGene, Ltd. | $6,800 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Ho | 2021 | |
| 2021-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $420 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2021 | |
| 2021-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $360 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2021 | |
| 2021-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $240 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2021 | |
| 2021-12-15 | SEAGEN INC. | $100 | Research payment | Cash or cash equivalent | A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies | 2021 | |
| 2021-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $60 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2021 | |
| 2021-12-14 | PFIZER INC. | $2,310 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB00 | 2021 |
| 2021-12-14 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB00 | 2021 |
| 2021-12-14 | PFIZER INC. | $660 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB00 | 2021 |
| 2021-12-13 | Janssen Research & Development, LLC | $11,436 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Dose Escalation Study of JNJ67571244 bispecific antibody targeting CD33 and CD3 in Subjects wit | 2021 | |
| 2021-12-13 | Janssen Research & Development, LLC | $2,271 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2021 | |
| 2021-12-13 | Janssen Research & Development, LLC | $2,000 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2021 | |
| 2021-12-13 | Janssen Research & Development, LLC | $92 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2021 | |
| 2021-12-10 | AstraZeneca Pharmaceuticals LP | $2,000 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Randomized Double-blind Placebo-controlled Phase III Study of Neoadjuvant Adjuvant Durvalumab and FLOT Chemotherapy Fo | 2021 |
| 2021-12-10 | Exelixis Inc. | $1,023 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2021 |
| 2021-12-10 | Alkermes, Inc. | $378 | Research payment | In-kind items and services | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-10 | Alkermes, Inc. | $259 | Research payment | In-kind items and services | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-09 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-09 | Regeneron Pharmaceuticals, Inc. | $9,492 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2021 | |
| 2021-12-09 | Genentech, Inc. | $4,344 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHII PLACEBO CONTROLLED OF TIRAGOLUMAB AND ATEZO IN NSCLC | 2021 |
| 2021-12-09 | Alkermes, Inc. | $3,400 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-09 | Alkermes, Inc. | $3,400 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-09 | Alkermes, Inc. | $3,400 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-09 | Genentech, Inc. | $1,982 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE I PROTOCOL COMBO FOR MULTIPLE MYELOMA WITH LENALIDOMIDE | 2021 |
| 2021-12-09 | Daiichi Sankyo Inc. | $1,051 | Research payment | Cash or cash equivalent | Turalio Drug, ONCOLOGY | PL3397-A-U126 | 2021 |
| 2021-12-09 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2021 | |
| 2021-12-09 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN LENALIDOMIDE IN RR FL DLBCL | 2021 |
| 2021-12-09 | Genentech, Inc. | $990 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN LENALIDOMIDE IN RR FL DLBCL | 2021 |
| 2021-12-09 | Regeneron Pharmaceuticals, Inc. | $660 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2021 | |
| 2021-12-09 | Regeneron Pharmaceuticals, Inc. | $600 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2021 | |
| 2021-12-09 | Janssen Research & Development, LLC | $200 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2021 | |
| 2021-12-09 | Alkermes, Inc. | $80 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-09 | Janssen Research & Development, LLC | $68 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2021 | |
| 2021-12-09 | Alkermes, Inc. | $68 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjec | 2021 | |
| 2021-12-08 | Regeneron Pharmaceuticals, Inc. | $101,055 | Research payment | Cash or cash equivalent | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN | 2021 | |
| 2021-12-08 | Regeneron Pharmaceuticals, Inc. | $5,440 | Research payment | Cash or cash equivalent | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN | 2021 | |
| 2021-12-08 | Regeneron Pharmaceuticals, Inc. | $5,440 | Research payment | Cash or cash equivalent | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN | 2021 | |
| 2021-12-08 | SEAGEN INC. | $4,154 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or | 2021 |
| 2021-12-08 | SEAGEN INC. | $2,000 | Research payment | Cash or cash equivalent | A Phase 1 Study of SEA-CD70 in Myeloid Malignancies | 2021 | |
| 2021-12-08 | SEAGEN INC. | $2,000 | Research payment | Cash or cash equivalent | A Phase 1 Study of SEA-CD70 in Myeloid Malignancies | 2021 | |
| 2021-12-08 | Genentech, Inc. | $422 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2021 |
| 2021-12-08 | SEAGEN INC. | $231 | Research payment | Cash or cash equivalent | TIVDAK Biological, Oncology | Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o | 2021 |
| 2021-12-08 | Regeneron Pharmaceuticals, Inc. | $84 | Research payment | Cash or cash equivalent | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN | 2021 | |
| 2021-12-08 | Regeneron Pharmaceuticals, Inc. | $84 | Research payment | Cash or cash equivalent | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN | 2021 | |
| 2021-12-07 | SEAGEN INC. | $10,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ADCETRIS Biological, Oncology | 2021 | |
| 2021-12-07 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T | 2021 |
| 2021-12-07 | Takeda Pharmaceuticals U.S.A., Inc. | $990 | Research payment | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T | 2021 |
| 2021-12-07 | Takeda Pharmaceuticals U.S.A., Inc. | $660 | Research payment | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T | 2021 |
| 2021-12-06 | Pharmacyclics LLC, an AbbVie Company | $39,787 | Research payment | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | A phase II multicenter single arm study to evaluate the efficacy and safety of single agent Brutons tyrosine kinase inhi | 2021 |
| 2021-12-06 | Genentech, Inc. | $5,000 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | LCMC3 | 2021 |
| 2021-12-06 | Janssen Research & Development, LLC | $398 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2021 | |
| 2021-12-03 | Merck Sharp & Dohme LLC | $14,439 | Research payment | Cash or cash equivalent | Biological, ONCOLOGY | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatin | 2021 |
| 2021-12-03 | Takeda Pharmaceuticals U.S.A., Inc. | $808 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2021 | |
| 2021-12-02 | Janssen Research & Development, LLC | $7,141 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2021 | |
| 2021-12-02 | Ipsen Bioscience Inc. | $2,000 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-02 | ABBVIE INC. | $369 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexa | 2021 |
| 2021-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $14,553 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2021 | |
| 2021-12-01 | Janssen Research & Development, LLC | $4,576 | Research payment | Cash or cash equivalent | A Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub | 2021 | |
| 2021-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $2,145 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2021 | |
| 2021-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $180 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2021 | |
| 2021-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $132 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2021 | |
| 2021-12-01 | Pharmacyclics LLC, an AbbVie Company | $80 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | 2021 |
| 2021-12-01 | Pharmacyclics LLC, an AbbVie Company | $80 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | 2021 |
| 2021-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $60 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2021 |
The latest 200 records of 1,836.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Detroit, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 638,530 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 639,111 | 1,793,561 | 10,077,331 |
| Median age B01002 | 35.2 | 37.9 | 40.2 |
| Under 18 B01001 | 24.8% | 23.6% | 21.2% |
| 65 and over B01001 | 15.1% | 16.6% | 18.6% |
| Households B11001 | 257,998 | 700,591 | 4,076,369 |
| Foreign born B05002 | 6.6% | 10.3% | 7.2% |
| Median household income B19013 | $39,938 | $60,539 | $72,875 |
| Median family income B19113 | $49,398 | $79,522 | $93,357 |
| Per capita income B19301 | $24,594 | $34,906 | $40,735 |
| Poverty rate B17001 | 32.7% | 20.8% | 13.2% |
| Unemployment rate B23025 | 14.0% | 8.7% | 5.7% |
| Civilian labor force B23025 | 268,955 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.8 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 18.1% | 27.6% | 32.4% |
| Housing units B25001 | 329,393 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 50.3% | 64.8% | 73.2% |
| Renters B25003 | 49.7% | 35.2% | 26.8% |
| Median home value B25077 | $83,900 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,074 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 10.8% | 47.9% | 72.4% |
| Black B03002 | 75.0% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 8.3% | 6.9% | 5.9% |
| Asian B03002 | 1.7% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.
Comments